Brought to you by 
Start-up Retrophin gains public status in reverse merger with Desert Gateway
19 Dec 2013
Executive Summary
Retrophin Inc., a 2011 private start-up focused on rare diseases, has achieved public status by reverse merging with the OTC-traded Desert Gateway Inc., which was founded in 2008 solely for the purpose of completing such a transaction. Desert Gateway does not conduct any business activities.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Start-up Retrophin gains public status in reverse merger with Desert Gateway
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice